Blueprint Medicines Corp (NASDAQ:BPMC) Director Lonnel Coats sold 10,000 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $82.40, for a total value of $824,000.00. Following the sale, the director now owns 10,000 shares in the company, valued at approximately $824,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of BPMC stock opened at $79.49 on Thursday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.52 and a current ratio of 7.52. Blueprint Medicines Corp has a 52-week low of $44.58 and a 52-week high of $102.98. The company has a market capitalization of $4.13 billion, a PE ratio of -14.75 and a beta of 1.55. The business’s fifty day moving average is $93.36 and its 200 day moving average is $84.46.
Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.92) by ($0.12). Blueprint Medicines had a negative return on equity of 73.73% and a negative net margin of 4,268.74%. The business had revenue of $5.11 million during the quarter, compared to analysts’ expectations of $1.39 million. During the same quarter last year, the business posted ($0.62) EPS. The company’s quarterly revenue was down 87.7% on a year-over-year basis. On average, sell-side analysts forecast that Blueprint Medicines Corp will post -8.45 EPS for the current fiscal year.
Several research firms have issued reports on BPMC. Deutsche Bank began coverage on Blueprint Medicines in a research report on Thursday, July 18th. They set a “buy” rating and a $110.00 target price on the stock. Robert W. Baird began coverage on Blueprint Medicines in a research report on Thursday, July 18th. They set an “outperform” rating and a $120.00 target price on the stock. Canaccord Genuity increased their target price on Blueprint Medicines from $105.00 to $120.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Cowen restated a “buy” rating on shares of Blueprint Medicines in a research report on Monday, June 17th. Finally, BidaskClub downgraded Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Thursday. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Blueprint Medicines has an average rating of “Buy” and an average target price of $110.11.
About Blueprint Medicines
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Further Reading: Catch-Up Contributions
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.